The IT injection of Newcastle disease virus combined with systemic injection of an anti-CTLA-4 antibody resulted in slower tumor growth, prolonged survival and protected the mice from a subsequent tumor rechallenge in a melanoma setting (126). Here, CTLA4 is linked to melanoma.